Clinical Trial Update: ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) [Phase 3]

View source ↗

Summary

Phase 3 trial of ADSTILADRIN (INSTILADRIN) in high-grade, BCG-unresponsive non-muscle invasive bladder cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• ADSTILADRIN (nadofaragene firadenovec)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Superficial Bladder Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-07-13